EBS

Emergent BioSolutions Inc.

$6.05

-0.82%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Source: Yahoo Finance
AI summary

Price & performance

1M-6.8%
3M-22.1%
YTD-52.8%
1Y-41.5%
52-week range—
Beta2.08
Full chart and returns against a benchmark

Q-Score

52/ 100

Quality against peers; 50 is the peer median.

Growth35
Risk44
Performance67
Valuation70
Profitability45
Leverage39
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$742.9M-28.8%
Net income$52.6M
Net margin7.1%+25.3 pts
Historical fundamentals

Revenue exposure

29%of revenue from outside the US
United States71%
Other Geographical Area18%
Canada10%
Largest customer46%
Regions, segments, customers and suppliers

Valuation

EBSIndustryP/E—35.25P/S0.482.74EV/EBITDA—16.35P/B0.992.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 2next report, after the close
EPS estimate$-0.39
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate